Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives

Despite advances in the understanding of the molecular biology of glioblastomas (GB), these neoplasms still are incurable with conventional therapies. Current efforts therefore focus on the development of new molecular approaches that exploit the genetic aberrations of cancer cells. Based on their f...

Full description

Saved in:
Bibliographic Details
Main Authors: Ronellenfitsch, Michael Wilfried (Author) , Steinbach, Joachim Peter (Author) , Wick, Wolfgang (Author)
Format: Article (Journal)
Language:English
Published: 19 September 2010
In: Targeted oncology
Year: 2010, Volume: 5, Issue: 3, Pages: 183-191
ISSN:1776-260X
DOI:10.1007/s11523-010-0154-5
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11523-010-0154-5
Get full text
Author Notes:Michael W. Ronellenfitsch, Joachim P. Steinbach, Wolfgang Wick
Description
Summary:Despite advances in the understanding of the molecular biology of glioblastomas (GB), these neoplasms still are incurable with conventional therapies. Current efforts therefore focus on the development of new molecular approaches that exploit the genetic aberrations of cancer cells. Based on their frequent activation or mutation in human GB and their paramount role for the maintenance of the neoplastic phenotype, both the epidermal growth factor receptor (EGFR) and the mammalian target of rapamycin (mTOR) are plausible targets for molecular therapies. However, clinical trials with drugs targeting EGFR or mTOR, so far, have produced largely disappointing results. In this article, we review strategies targeting EGFR and mTOR as therapies for malignant glioma. Recent advances in the understanding of the complex signaling network involved are highlighted and the results of clinical trials are summarized. Mechanisms of resistance are explored, and potential future directions as well as trends in preclinical and clinical development are discussed.
Item Description:Gesehen am 15.06.2023
Physical Description:Online Resource
ISSN:1776-260X
DOI:10.1007/s11523-010-0154-5